CEL-SCI Corporation Stock NYSE
Stocks
US1508375086
Biotechnology & Medical Research
| Market Cap | 28.67M 24.66M 23.19M 21.17M 39.59M 2.71B 39.72M 275M 106M 1.39B 108M 105M 4.42B | P/E 2026 * |
-0.53x | P/E 2027 * | -0.26x |
|---|---|---|---|---|---|
| Enterprise Value | 23.12M 19.88M 18.7M 17.07M 31.92M 2.19B 32.02M 222M 85.69M 1.12B 86.81M 84.91M 3.57B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.91x |
| Free-Float |
93.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| 18/07/23 | Wall Street sluit hoger | |
| 18/07/23 | Wall Street op winst | |
| 18/07/23 | Wall Street richting licht rode opening | |
| 18/07/23 | Futures voorspellen terughoudende opening Wall Street | |
| 28/06/21 | Cel-Sci presenteert positieve onderzoeksdata immunotherapie |
| 1 day | -0.36% |
| Manager | Title | Age | Since |
|---|---|---|---|
Geert Kersten
CEO | Chief Executive Officer | 67 | 01/01/1995 |
Patricia Prichep
DFI | Director of Finance/CFO | 75 | 13/11/2024 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Geert Kersten
BRD | Director/Board Member | 67 | 01/01/1995 |
| Director/Board Member | 73 | 22/06/2015 | |
Bob Watson
CHM | Chairman | 69 | 08/07/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36% | -14.33% | - | - | 28.67M | |
| -0.38% | -2.64% | +42.69% | +99.03% | 67.98B | |
| -2.71% | -0.71% | +34.08% | +81.43% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +377.83% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -13.58% | 26.06B | |
| -1.42% | -4.28% | +31.24% | +13.27% | 25.74B | |
| -1.11% | +0.90% | +23.12% | -18.50% | 20.09B | |
| +1.15% | -14.24% | +219.82% | +381.14% | 17.16B | |
| +0.20% | -4.68% | -6.41% | +560.92% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +165.57% | 14.62B | |
| Average | -0.43% | +1.05% | +42.18% | +183.01% | 31.01B | |
| Weighted average by Cap. | -0.81% | +0.59% | +36.97% | +141.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 5.97M 5.14M 4.83M 4.41M 8.25M 565M 8.27M 57.27M 22.14M 289M 22.43M 21.94M 921M |
| Net income | -25.08M -21.57M -20.29M -18.52M -34.64M -2.37B -34.75M -241M -92.99M -1.21B -94.2M -92.14M -3.87B | -29.51M -25.38M -23.87M -21.79M -40.76M -2.79B -40.89M -283M -109M -1.43B -111M -108M -4.55B |
| Net Debt | -5.55M -4.78M -4.49M -4.1M -7.67M -525M -7.69M -53.27M -20.59M -269M -20.86M -20.4M -857M | -5.34M -4.59M -4.32M -3.94M -7.37M -505M -7.4M -51.2M -19.79M -259M -20.05M -19.61M -824M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
